Nonprofit Funding Platform Heroe5 Launches The Good Society, Embracing Web3 Approach to the Sustainable Financial Benefit for Charities
14.9.2022 15:49:00 EEST | Business Wire | Press release
Nonprofit funding platform Heroe5™ announced today the creation of The Good Society™ to address the growing need for sustainable funding platforms for charitable organizations. The Good Society becomes the first project focused on Web3 solutions to raise awareness and support global causes working to positively impact our communities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005376/en/
“The Good Society is a vital next step in the evolution of the fundraising industry: a Web3 platform to create art impact experiences,” said Sebastien Heimann, founding member and CEO of Heroe5 and The Good Society. “As the world moves to Web3, charities need more fundraising tools to stay ahead of the curve and embrace new ways to engage potential donors. The Good Society will provide those innovations, allowing them to raise critical funding and awareness for vital causes while feeding the public’s growing interest in digital collectables.”
With each drop 1800 digital collectibles designed by acclaimed artists will be released each month supporting a broad range of nonprofits working to improve the environment, wildlife, human rights, and our collective health and wellbeing. A percentage of these art impact experiences will grant token carriers access to unique events in perpetuity.
Artist Nate Mohler created “Out of Sight | Out of Mind” for The Good Society’s first program, which benefits Lonely Whale, No More Plastic, and Oceanic Global. The digital collectables, scaled to 3840 x 3840 pixels, 26 seconds in length and layered with “white sound,” emphasize the risk to fragile ocean ecosystems from the human-caused plastic pollution in urban environments and highlight how much there is left to learn. Three of the many cities featured in “Out of Sight | Out of Mind” include London, Los Angeles, and Paris.
“No matter where you live, the oceans provide the oxygen you breathe, nurture the food you eat, and regulate the temperature of the air. Without a healthy ocean we’d have a very different experience on land,” said Mohler. “This series is not of the oceans but of major cities, which emit 60% of all carbon emissions and make up less than 1% of the Earth’s surface. Similar to my ongoing series ‘Painted Cities’ there are three unique styles intended to bring a more ephemeral and dreamlike memory of the city.”
One of every 15 of the digital collectibles will also provide owners access to experiences that are provided by the benefiting organizations and artists for each drop. Some of the experiences tied to this premier release include:
- Two front row seats at Paris Fashion Week
- Two passes to Oceanic Global’s annual gathering for ocean conservation
- An annual artist critique call with Nate Mohler
- Invitations to Lonely Whale's annual leadership virtual town hall which discuss its programs and preview its impact report
Digital collectors will easily be able to purchase the artwork with a credit card or Tez, cryptocurrency of the Tezos blockchain, when they are minted on August 12 at 2pm ET. Once sold out, more than $1M (US) in new funding will be available to the benefiting organizations and, as the digital collectables are resold, the organizations will receive residual payments from each transaction.
Quotes from Benefiting Organizations
“Lonely Whale’s goal is simple - to keep plastic out of the ocean. We want to thank each person who buys one of Nate Mohler’s striking NFTs through The Good Society, which will support the creative development and market adoption of alternatives to thin-film plastic and directly address the nearly 180 billion polybags used every year by the fashion industry.” – Harry Bernstein, Chief Creative Officer, Lonely Whale
“Plastic pollution has become one of the biggest environmental scourges of our time. Microplastics are everywhere: in the deep ocean, in Antarctic ice, even falling rain over mountains and cities. Plastic pollution not only pollutes our planet; it pollutes our blood. We must act and the time is now. We are grateful to The Good Society for entrusting No More Plastic Foundation with this generous funding. With it, we will continue our work to end the cycle of plastics and microplastics flowing into our ocean.” – Rosalie Mann, Founder & President, No More Plastic
“We live on a blue planet. The ocean covers 70% of the surface of the earth and produces every other breath we take. Our well-being is intrinsically tied to the ocean. Thanks to The Good Society and their innovative fundraising platform and model – and to artiste extraordinaire Nate Mohler – Oceanic Global will be able to keep empowering individuals, communities, and industries to create positive change for a thriving ocean.” – Lea d'Auriol, Founder & Executive Director, Oceanic Global
About The Good Society
The Good Society harnesses the power of non fungible tokens to fund global initiatives. Designed by acclaimed digital artists, every month a new NFT will drop that raises awareness and secures funding for nonprofits working to improve the environment, human rights, and our collective health and wellbeing. Led by Sebastien Heimann, the Co-founder & CEO of fundraising platform Heroe5, The Good Society leverages the uniqueness of Web3 to deliver a powerful and recurring source of funding. For more information visit thegoodsociety.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005376/en/
Contact information
Press
Famous Last Words PR
Carolyn Zweifel: carolyn@flwpr.com
Fred Shank: fred@flwpr.com
Jen Peros: jen@flwpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
